Sorrento Therapeutics Inc. (NASDAQ: SRNE) has announced that its COVI-STIX COVID-19 Rapid Antigen Detect Test will be utilized to screen attendees for the 59Th World Boxing Council Annual Convention happening in Mexico City, Mexico.
COVI-STIX COVID-19 to be used at WBC event
Currently testing remains a crucial part of the effective planning of any public event, including boxing matches with large crowds. As a result, Sorrento Therapeutics Mexico has partnered with the World Boxing Council to deliver COVI-STIX quick testing for the event. In addition, the two organizations have pledged to work together to provide solutions to the boxing sport other sports and entertainment events.
Prior to registration, all conference attendees will be given COVI-STIX tests, and a local testing laboratory will issue testing and travel certificates to those overseas visitors who require proof of testing for international travel.
Many celebrities, like Julio César Chávez, Larry Holmes, Floyd Mayweather, Oscar De La Hoya, Roberto Durán, and Antonio Tarver, will be in Mexico City for the “Together Again” convention, as will many other heroes from the past and present, including boxing’s biggest superstar Canelo Alvarez.
Abivertinib suppresses EGFR mutation s
Sorrento announced the publication of positive results from the pivotal abivertinib study on22 NSCLC patients that had been heavily pretreated in the Clinical Cancer Research journal. Guangdong Lung Cancer Institute’s Professor Dr. Yi-Long Wu authored the publication. Wu was an International Association for the Study of Lung cancer Scientific Award awardee in 2017, and he was the study’s principal investigator.
Abivertiinib, which is a third-generation EGFR/BTK inhibitor that is pyrilopyrimidine-based that is different from osimertinib. When compared to wild-type EGFR, abivertinib specifically suppresses EGFR-activating and resistant mutations with almost 300 times potency. The 300 mg BID abivertinib dose was chosen based on previous trials’ pharmacokinetics, effectiveness, and safety profiles.
Sorrento CEO Dr. Henry Ji said, “We are very encouraged by the publication of these significant positive results of abivertinib on the treatment of advanced and heavily pretreated NSCLC lung cancer in Clinical Cancer Research and look forward to bringing abivertinib into the armamentarium of this multi-billion dollar indication.”
